Clinical Trial Update: Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI [Phase 2]

View source ↗

Summary

A completed Phase 2 trial assessed the feasibility and safety of the REG1 Anticoagulation System compared with unfractionated heparin in elective PCI.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• REG1 Anticoagulation System (REG1)
• Unfractionated Heparin (unfractionated heparin)

Snippet

Sponsor: Regado Biosciences, Inc. | Conditions: Coronary Artery Disease | Phase 2 | Status: COMPLETED